Malignant mesothelioma is a rare type of cancer that is
characterised by tumor formation in the mesothelium, a tissue layer that covers
the pleural organs such as heart, abdomen, lungs and other organs. The biggest
risk factor of the disease is exposure to asbestos, a silicate mineral. Some of
the major symptoms of the disease include cough, shortness of breath and pain in
the chest. The symptoms in malignant mesothelioma could take as long as 30 to
50 years to show. Surgery, chemotherapy and radiotherapy are some of the major
options available for the treatment of malignant mesothelioma. The prevalence
of the disease is not known; however, it is estimated that malignant
mesothelioma accounts for approximately 1% of all cancers globally. According to the cancer research, in the U.K., 48%
cases of malignant mesothelioma are of people above the age of 75 years.
Explore Report at: https://www.psmarketresearch.com/market-analysis/malignant-mesothelioma-therapeutics-pipeline-analysis
The therapeutics pipeline for malignant mesothelioma is
expected to witness considerable growth in the near future on account of
increasing exposure of general population to pollutants such as asbestos as a
result of rising level of pollution in the environment, eventually leading to
increasing prevalence of the disease. Other factors that are expected to
contribute to the growth in the therapeutics pipeline of malignant mesothelioma
include poor prognosis of the disease, growing healthcare investment on cancer
treatments and rising geriatric population.
Some of the major players involved in the development of therapeutics for the treatment of malignant mesothelioma include AstraZeneca plc, Boehringer Ingelheim GmbH, Polaris Pharmaceuticals, Inc., PharmaMar S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Co., Ltd., Bayer AG, Aduro Biotech, Inc., Calithera Biosciences, Inc., CBT Pharmaceuticals, Inc.
No comments:
Post a Comment